Enliven Therapeutics, Inc. (ELVN)
(Real Time Quote from BATS)
$18.83 USD
+0.26 (1.40%)
Updated Sep 26, 2025 10:00 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELVN 18.83 +0.26(1.40%)
Will ELVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for ELVN
NR7 appears for ELVN after 3.28% move
NR7 appears for ELVN after 0.05% move
ELVN Fell Below 20 Day Moving Average on September 23
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuticals Inc
Is ELVN ready to move higher? Crossed Above 20 Day Moving Average shows up after rocketing 5.06%